Should non‑pharmacologic airway‑clearance therapies such as incentive spirometry, EzPAP, or Acapella be implemented for the general skilled‑nursing‑facility population as part of a wellness program to prevent respiratory complications?

Recommendation: Do Not Implement Routine Airway Clearance Therapies in General SNF Populations

Nonpharmacologic airway clearance therapies such as incentive spirometry, EzPAP, or Acapella should NOT be implemented as routine wellness interventions for the general skilled nursing facility population without specific respiratory indications.

Evidence-Based Rationale

The ACCP evidence-based guidelines 1 explicitly state that the effect of nonpharmacologic airway clearance techniques on long-term outcomes such as health-related quality of life, exacerbations, hospitalizations, and mortality is not known. This is a critical gap when considering preventive use in asymptomatic populations.

Key Guideline Findings Against Routine Use:

• No proven benefit in general populations: The 2013 AARC clinical practice guideline 2 specifically recommends against routine prophylactic use of incentive spirometry in postoperative patients and states that ACT is not recommended if the patient can mobilize secretions with cough

• Limited to specific disease states: All guideline recommendations are restricted to patients with:

  • Cystic fibrosis with copious secretions
  • Neuromuscular disease with impaired cough
  • Bronchiectasis with symptomatic secretion retention
  • Not for general wellness or prevention

• Potential harm in some populations: The guidelines explicitly warn that in persons with airflow obstruction like COPD, manually assisted cough may be detrimental and should not be used (Grade D recommendation) 1

Clinical Context for SNF Populations

The systematic review 3 examining 2,453 hospitalized patients found that airway clearance interventions "typically provided small benefits... but differences between groups were generally small and not significant." This marginal benefit does not justify routine implementation in asymptomatic residents.

When Airway Clearance IS Appropriate:

Only implement these therapies for residents with:

1. Neuromuscular disease with impaired cough (peak cough flow <270 L/min) - use mechanical cough assist devices 1
2. Cystic fibrosis - PEP therapy or oscillatory devices 1
3. Symptomatic secretion retention despite ability to cough - guided by patient tolerance and effectiveness 2
4. Bronchiectasis during acute exacerbations requiring antibiotic therapy 4

Critical Pitfalls to Avoid:

• Do not confuse disease-specific interventions with wellness programs: These devices were studied in patients with specific pathology, not healthy or general elderly populations
• Resource misallocation: Staff time and equipment costs are better directed toward proven interventions like early mobilization and ambulation 2
• False sense of prevention: No evidence supports these therapies prevent pneumonia or respiratory complications in general populations 2, 3

What TO Implement Instead:

For a general SNF wellness program focused on respiratory health:

• Early mobility and ambulation - this has actual evidence for reducing postoperative complications and promoting airway clearance 2
• Teaching effective cough technique to residents who can cooperate 2
• Vaccination programs and infection control measures 5
• Smoking cessation support for current smokers 5

The evidence is clear: airway clearance devices are therapeutic tools for specific respiratory conditions, not preventive wellness interventions for general populations. Their routine use would represent an evidence-free practice that diverts resources from interventions with proven benefit.